IDHIRA: a prospective, observational study on ivosidenib in patients with IDH1 R132-mutated advanced cholangiocarcinoma.
Marlies Michl, Nora Hagemeyer, Marion Looß...
https://pubmed.ncbi.nlm.nih.gov/40028796/Actively Recruiting
Led by iOMEDICO AG · Updated on 2026-10-22
100
Participants Needed
19
Research Sites
N/A
Total Duration
Cholangiocarcinoma is a rare and aggressive bile duct tumor with limited treatment options and a poor prognosis. Researchers are collecting real-world data on the use of the targeted drug ivosidenib in adults with locally advanced or metastatic cholangiocarcinoma who have an IDH1 R132 mutation and have already received at least one prior systemic therapy. This prospective, multicenter observational study in Germany aims to provide evidence on the effectiveness, quality of life, and safety of ivosidenib in a broad patient population. Ivosidenib will be given following the current summary of product characteristics SmPC. The study will observe patients treated with ivosidenib in routine clinical practice without altering their treatment. Data will be gathered over a maximum period of 38 months from first patient inclusion to last patient last visit, covering treatment duration and patient outcomes during this time. Participants will be monitored regularly to assess progression-free survival as the primary outcome, along with overall survival, response rates, adverse events, and quality of life measures related to cholangiocarcinoma. The study also collects information on dose modifications, treatment duration, previous therapies, concomitant medications, and physician treatment decisions. This observational study continues until December 2027, allowing long-term follow-up of patients receiving ivosidenib.
CONDITIONS
Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study
S
Sina Grebhardt, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
iOMEDICO AG
Lead Sponsor
Servier Deutschland GmbH
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 38 months
Participants receive ivosidenib as part of their routine medical care. Researchers collect data on treatment effects, safety, quality of life, and disease progression over time.
Regular visits as per routine care
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Marlies Michl, Nora Hagemeyer, Marion Looß...
https://pubmed.ncbi.nlm.nih.gov/40028796/iOMEDICO AG
Lead Sponsor
Servier Deutschland GmbH
Collaborating Sponsor